← All trials
NCT05979844
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 6, 2023
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- Aug 7, 2023
- Last posted
- Oct 25, 2023
- Enrollment
- 16
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Department of Veteran AffairsLead sponsor
- MAPS Public Benefit CorporationCollaborator
- Department of Veteran AffairsCollaborator
- Department of Veteran AffairsOverall official - principal investigator
- Department of Veteran AffairsSponsor investigator
- Healing BreakthroughCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.